## Contents

### 1 New Drug Development

1.1 Introduction ........................................... 1
1.2 Origin and Goals of the Book ................... 2
1.3 The Discipline of Statistics ......................... 2
1.4 A Lifecycle Perspective on Drug Development .......... 3
1.5 Design, Conduct, and Analysis .................. 4
  1.5.1 Compelling Evidence ............................. 4
1.6 Drug Discovery ......................................... 4
1.7 Nonclinical Development Programs .................. 5
1.8 Clinical Development Programs .................... 5
  1.8.1 Ethical Conduct .................................. 6
  1.8.2 Different Studies in a Clinical Development Program ..... 7
1.9 Manufacturing ...................................... 8
1.10 Definitions of Clinical Research and Clinical Trials .... 9
  1.10.1 Clinical Research ................................ 9
  1.10.2 Clinical Trials .................................. 10
1.11 Operational Execution ............................ 10
1.12 The Central Importance of Biological Considerations .... 10

### 2 The Regulatory Environment

2.1 Introduction ...................................... 11
  2.1.1 Goals of the ICH ............................... 12
2.2 The Food and Drug Administration ................. 12
  2.2.1 The Code of Federal Regulations .............. 13
2.3 cGMP, cGLP, and cGCP ............................ 14
2.4 Regulatory Aspects of New Drug Development ... 14
2.5 Sponsor and Regulatory Agency Responsibilities .... 15
2.6 The Investigational New Drug Application .......... 15
  2.6.1 Review of the Investigational New Drug Application 17
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.7</td>
<td>The New Drug Application</td>
<td>19</td>
</tr>
<tr>
<td>2.7.1</td>
<td>Statistical Review of the New Drug Application</td>
<td>19</td>
</tr>
<tr>
<td>Further Readings</td>
<td></td>
<td>20</td>
</tr>
<tr>
<td>3</td>
<td>Drug Discovery</td>
<td>21</td>
</tr>
<tr>
<td>3.1</td>
<td>Introduction</td>
<td>21</td>
</tr>
<tr>
<td>3.1.1</td>
<td>Small Molecule Drug Candidates</td>
<td>21</td>
</tr>
<tr>
<td>3.1.2</td>
<td>Biopharmaceutical Drug Candidates</td>
<td>22</td>
</tr>
<tr>
<td>3.2</td>
<td>Overview of Pharmaceutics, Pharmacokinetics, and Pharmacodynamics</td>
<td>22</td>
</tr>
<tr>
<td>3.2.1</td>
<td>Drug Receptors</td>
<td>23</td>
</tr>
<tr>
<td>3.2.2</td>
<td>The Pharmacodynamic Phase</td>
<td>23</td>
</tr>
<tr>
<td>3.2.3</td>
<td>The Pharmacokinetic Phase</td>
<td>24</td>
</tr>
<tr>
<td>3.2.4</td>
<td>The Pharmaceutical Phase</td>
<td>25</td>
</tr>
<tr>
<td>3.3</td>
<td>Medicinal Chemistry</td>
<td>25</td>
</tr>
<tr>
<td>3.3.1</td>
<td>Drug Molecules</td>
<td>26</td>
</tr>
<tr>
<td>3.3.2</td>
<td>Macromolecules, Receptors, and Drug Targets</td>
<td>26</td>
</tr>
<tr>
<td>3.3.3</td>
<td>Structure–Activity Considerations and Drug–Receptor Interactions</td>
<td>27</td>
</tr>
<tr>
<td>3.4</td>
<td>Cheminformatics, Bioinformatics, and Computer-Aided Molecular Design</td>
<td>28</td>
</tr>
<tr>
<td>3.4.1</td>
<td>Bioinformatics</td>
<td>29</td>
</tr>
<tr>
<td>3.5</td>
<td>Biologicals</td>
<td>30</td>
</tr>
<tr>
<td>3.5.1</td>
<td>Molecular Genetics and Proteins</td>
<td>30</td>
</tr>
<tr>
<td>3.5.2</td>
<td>Protein Structures</td>
<td>31</td>
</tr>
<tr>
<td>3.5.3</td>
<td>Recombinant DNA Technology</td>
<td>31</td>
</tr>
<tr>
<td>3.5.4</td>
<td>Recombinant Proteins As Drugs</td>
<td>32</td>
</tr>
<tr>
<td>3.5.5</td>
<td>Discovery and Development of Biopharmaceuticals</td>
<td>33</td>
</tr>
<tr>
<td>3.6</td>
<td>Moving to Nonclinical Research</td>
<td>34</td>
</tr>
<tr>
<td>Further Readings</td>
<td></td>
<td>34</td>
</tr>
<tr>
<td>4</td>
<td>Nonclinical Research</td>
<td>35</td>
</tr>
<tr>
<td>4.1</td>
<td>Introduction</td>
<td>35</td>
</tr>
<tr>
<td>4.1.1</td>
<td>Reduction, Refinement, and Replacement of Laboratory Animal Studies</td>
<td>35</td>
</tr>
<tr>
<td>4.2</td>
<td>Pharmacokinetics</td>
<td>36</td>
</tr>
<tr>
<td>4.2.1</td>
<td>Absorption</td>
<td>36</td>
</tr>
<tr>
<td>4.2.2</td>
<td>Distribution</td>
<td>37</td>
</tr>
<tr>
<td>4.2.3</td>
<td>Metabolism</td>
<td>37</td>
</tr>
<tr>
<td>4.2.4</td>
<td>Elimination</td>
<td>38</td>
</tr>
<tr>
<td>4.3</td>
<td>Pharmacology</td>
<td>38</td>
</tr>
<tr>
<td>4.3.1</td>
<td>Research Pharmacology Studies</td>
<td>38</td>
</tr>
<tr>
<td>4.3.2</td>
<td>Safety Pharmacology Studies</td>
<td>39</td>
</tr>
<tr>
<td>4.4</td>
<td>Toxicological Studies</td>
<td>39</td>
</tr>
<tr>
<td>4.4.1</td>
<td>Toxicodynamics</td>
<td>40</td>
</tr>
</tbody>
</table>
4.4.2 Exploratory Toxicology Studies ......................... 40
4.4.3 Pre-FIH Regulatory Toxicology Studies .................. 41
4.4.4 Post-FIH Regulatory Toxicology Studies .................. 41
4.4.5 Dose Range-Finding Toxicology .......................... 41
4.4.6 Genotoxicity .......................................... 42

4.5 Assessment of QT Interval Prolongation .................... 42
4.5.1 Long QT Syndrome: Underlying Molecular Biology .......... 43
4.5.2 Drug-Induced QT Interval Prolongation .................... 44
4.5.3 Associated Nonclinical Testing .......................... 45
4.5.4 Short QT Syndrome .................................... 45

Further Readings ............................................. 46

5 Designing Clinical Trials ..................................... 47
5.1 Introduction .............................................. 47
5.2 Classification of Clinical Trials ............................ 47
5.3 Human Pharmacology Trials ................................. 49
5.4 Clinical Pharmacokinetics and Pharmacodynamics ............... 51
5.4.1 Pharmacokinetic Parameters ............................ 52
5.4.2 Fasting and Fed Pharmacokinetics ....................... 52
5.4.3 Absorption and Bioavailability .......................... 53
5.4.4 Distribution ............................................ 54
5.4.5 Metabolism ............................................. 54
5.4.6 Elimination/Clearance .................................. 55
5.5 Therapeutic Exploratory Trials .............................. 55
5.6 Therapeutic Confirmatory Trials ............................. 56
5.7 Therapeutic-Use Trials ..................................... 56
5.8 Study Design ............................................. 56
5.9 Ethical Aspects of Design ................................... 57
5.10 Study Design in Drug Clinical Trials ....................... 57
5.10.1 The Parallel Group Design ............................. 58
5.10.2 The Cross-over Design ................................ 59
5.10.3 Respective Advantages of the Parallel Group and Cross-over Designs ..................... 59
5.10.4 Focus on the Parallel Group Design in This Book .............. 60
5.11 Central Principles of Experimental Design in Clinical Trials ........................................... 60
5.11.1 Replication ........................................... 61
5.11.2 Randomization ......................................... 61
5.11.3 Local Control ......................................... 64
5.11.4 Good Design Simplifies and Validates the Accompanying Analyses ..................... 64
5.11.5 Sample Size Estimation ............................... 65
5.12 The Clinical Study Protocol ........................................... 65
  5.12.1 Inclusion and Exclusion Criteria ............................... 66
  5.12.2 The Primary Objective ............................................. 66
Further Readings ................................................................. 67

6 Conducting Clinical Trials I: Experimental Methodology .......... 69
  6.1 Introduction .............................................................. 69
  6.2 Blood Pressure Measurement in Clinical Trials ................... 70
    6.2.1 Hypertension ....................................................... 70
    6.2.2 Surrogate Endpoints in Clinical Trials ...................... 71
    6.2.3 Arterial Blood Pressure ......................................... 72
    6.2.4 Assessing Blood Pressure Change over Time ............... 73
    6.2.5 A Cautionary Tale: Blood Pressure Measurement at Your Doctor’s Office ........................................... 74
    6.2.6 A Cautionary Tale for Clinical Trial Blood Pressure Measurements ......................................................... 75
  6.3 Central Labs ............................................................. 75
    6.3.1 Operational Considerations .................................... 76
  6.4 Core ECG Labs .......................................................... 77
  6.5 The Case Report Form .................................................. 77
Further Readings ................................................................. 78

7 Conducting Clinical Trials II: Operational Execution ............ 79
  7.1 Introduction .............................................................. 79
  7.2 The Outsourcing Process .............................................. 80
  7.3 Feasibility Evaluations ............................................... 80
    7.3.1 More Extensive Feasibility Evaluations ..................... 81
    7.3.2 Feasibility Reporting ............................................ 82
  7.4 Standard Operating Procedures ..................................... 82
    7.4.1 Balancing the Degree of Flexibility Within an SOP .......... 83
    7.4.2 The Necessity of Implementing and Maintaining SOPs .......... 83
  7.5 Project Management .................................................... 84
  7.6 Site and Investigator Recruitment .................................. 85
    7.6.1 Principal Investigators ......................................... 85
    7.6.2 Responsibilities of Principal Investigators ................ 86
    7.6.3 Potential Principal Investigators in Private Practice Settings ................................................................. 86
    7.6.4 Potential Principal Investigators at Larger Medical Institutions ................................................................. 86
    7.6.5 Principal Investigator Training ................................ 87
  7.7 Subject Recruitment and Retention ................................ 88
    7.7.1 Subject Recruitment .............................................. 88
    7.7.2 Subject Retention ................................................. 89
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.8</td>
<td>Monitoring Clinical Trials</td>
<td>90</td>
</tr>
<tr>
<td>7.9</td>
<td>Data Management</td>
<td>91</td>
</tr>
<tr>
<td>7.9.1</td>
<td>Data Management Plans</td>
<td>91</td>
</tr>
<tr>
<td>7.9.2</td>
<td>Electronic Data Capture</td>
<td>92</td>
</tr>
<tr>
<td>7.9.3</td>
<td>Database Development</td>
<td>92</td>
</tr>
<tr>
<td>7.10</td>
<td>A New Paradigm: Allying With Sponsors</td>
<td>93</td>
</tr>
<tr>
<td>7.11</td>
<td>Underperforming and Non-performing Clinical Trial Sites</td>
<td>93</td>
</tr>
<tr>
<td>7.11.1</td>
<td>Limitations of the Current Model</td>
<td>95</td>
</tr>
<tr>
<td>7.12</td>
<td>Another New Paradigm: The Site-Specific CRO</td>
<td>95</td>
</tr>
<tr>
<td>7.12.1</td>
<td>Synergies of a Sponsor CRO and a Site-Specific CRO Working Together</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>Further Readings</td>
<td>97</td>
</tr>
<tr>
<td>8</td>
<td>Statistical Analysis</td>
<td>99</td>
</tr>
<tr>
<td>8.1</td>
<td>Introduction</td>
<td>99</td>
</tr>
<tr>
<td>8.2</td>
<td>Types of Clinical Data</td>
<td>100</td>
</tr>
<tr>
<td>8.2.1</td>
<td>Numerical Variables</td>
<td>100</td>
</tr>
<tr>
<td>8.2.2</td>
<td>Categorical Variables</td>
<td>100</td>
</tr>
<tr>
<td>8.2.3</td>
<td>Parametric Tests and Nonparametric Tests</td>
<td>101</td>
</tr>
<tr>
<td>8.3</td>
<td>Descriptive Statistics: Summarizing Data</td>
<td>101</td>
</tr>
<tr>
<td>8.3.1</td>
<td>Measures of Central Tendency</td>
<td>101</td>
</tr>
<tr>
<td>8.3.2</td>
<td>Measures of Dispersion Around a Central Value</td>
<td>102</td>
</tr>
<tr>
<td>8.4</td>
<td>Inferential Statistics: Hypothesis Testing</td>
<td>103</td>
</tr>
<tr>
<td>8.4.1</td>
<td>The Search for Compelling Evidence</td>
<td>103</td>
</tr>
<tr>
<td>8.4.2</td>
<td>Variation and Systematic Variation</td>
<td>103</td>
</tr>
<tr>
<td>8.4.3</td>
<td>Between-Groups Variation and Within-Groups Variation</td>
<td>104</td>
</tr>
<tr>
<td>8.4.4</td>
<td>Comparing Between-Groups Variance and Within-Groups Variance</td>
<td>104</td>
</tr>
<tr>
<td>8.4.5</td>
<td>The Term Error Does Not Imply a Mistake</td>
<td>105</td>
</tr>
<tr>
<td>8.5</td>
<td>Probability</td>
<td>105</td>
</tr>
<tr>
<td>8.5.1</td>
<td>Likely Events Do Not Always Happen</td>
<td>106</td>
</tr>
<tr>
<td>8.5.2</td>
<td>Clinical Decision-Making</td>
<td>106</td>
</tr>
<tr>
<td>8.5.3</td>
<td>Sampling Theory</td>
<td>107</td>
</tr>
<tr>
<td>8.5.4</td>
<td>The Standard Error of the Mean</td>
<td>107</td>
</tr>
<tr>
<td>8.6</td>
<td>The Normal Distribution</td>
<td>108</td>
</tr>
<tr>
<td>8.6.1</td>
<td>Area Under the Normal Curve</td>
<td>110</td>
</tr>
<tr>
<td>8.6.2</td>
<td>Various Areas Under the Normal Curve</td>
<td>111</td>
</tr>
<tr>
<td>8.7</td>
<td>Analysis of Association</td>
<td>111</td>
</tr>
<tr>
<td>8.7.1</td>
<td>Direction of an Association</td>
<td>112</td>
</tr>
<tr>
<td>8.7.2</td>
<td>Degree of Closeness of an Association</td>
<td>112</td>
</tr>
<tr>
<td>8.7.3</td>
<td>Correlation Coefficients</td>
<td>112</td>
</tr>
<tr>
<td>8.7.4</td>
<td>Determining the Significance of a Product Moment Coefficient</td>
<td>113</td>
</tr>
</tbody>
</table>
8.7.5 The Coefficient of Determination
8.7.6 Association Does Not Necessarily Equate to Causation

9 Statistical Significance
9.1 Introduction
9.2 Creating a Research Question and Associated Hypotheses
9.2.1 The Research Hypothesis
9.2.2 The Null Hypothesis
9.3 Precise Expression of the Research Hypothesis and the Null Hypothesis: The Concept of Statistical Significance
9.4 Hypothesis Testing
9.5 Conducting a Statistical Test and Obtaining a Test Statistic
9.6 The Independent Groups t-Test
9.6.1 Degrees of Freedom
9.6.2 Format of Results from an Independent Groups t-Test
9.6.3 The p-Value: Its Definition and Meaning
9.6.4 The p-Value and Hypothesis Testing
9.6.5 Two More Examples of Results from an Independent Groups t-Test
9.7 The Dependent Measures t-Test
9.8 Analysis of Variance
9.9 One-Factor Independent Groups ANOVA
9.9.1 The Test Statistic in ANOVA
9.9.2 Calculation of the F-Test
9.9.3 A Further Analytical Step: Multiple Comparisons
9.10 General Comments on Multiple-Comparison Testing
9.11 Possible Clinical Interpretations of Statistical Results

10 Clinical Significance
10.1 Introduction
10.2 The Logic of Confidence Intervals
10.3 Confidence Intervals for a Sample Mean
10.3.1 A More Precise Definition of a Confidence Interval
10.4 Confidence Intervals for the Difference Between Treatment Group Means
10.5 Relationship of the 95% CI and 99% CI to the 0.05 and 0.01 p-Values
10.6 The Additional Benefit of Using Confidence Intervals
10.6.1 Clinical Relevance and Clinically Relevant Differences
11 Sample Size Estimation
11.1 Introduction ........................................ 143
11.2 Ethical Issues in Sample Size Estimation ............ 144
11.3 Variables Involved in Sample Size Estimation ......... 145
11.4 Type I and Type II Errors ............................ 146
  11.4.1 The Implications of Type I and Type II Errors.... 146
11.5 Choosing the Variables Needed for Sample Size Estimation ........................................ 147
  11.5.1 Alpha and Beta .................................... 147
  11.5.2 The Treatment Effect, Its Variance, and the Standardized Treatment Effect .............. 148
11.6 Using the Appropriate Formula to Yield the Sample Size ........................................ 148
11.7 Influences on the Sponsor’s Choice of These Values ........................................ 149
11.8 Choosing the Objective(s) on Which to Base the Sample Size Estimation ..................... 150
11.9 Other Issues to Keep in Mind .......................... 150

12 General Safety Assessments .......................... 153
12.1 Introduction ........................................ 153
12.2 Operationalizing the Term Drug Safety ............... 153
  12.2.1 Perspectives of Regulators and Prescribing Physicians on Safety Data ..................... 154
12.3 General Safety Assessments .......................... 155
  12.3.1 Extent of Exposure .................................. 156
  12.3.2 Adverse Events .................................... 156
  12.3.3 Common Laboratory Tests .......................... 157
  12.3.4 Vital Signs .......................................... 159
12.4 Acquisition and Management of Safety Data .......... 159
  12.4.1 Adverse Events .................................... 159
  12.4.2 Serious Adverse Event Data ........................ 160
12.5 Analysis Populations ................................ 161
12.6 Presentation of Safety Data .......................... 161
  12.6.1 Descriptive Approaches to Safety Data .......... 162
  12.6.2 Time-to-Event Analysis ............................ 163
  12.6.3 Differences Between Approaches to Safety and Efficacy Data ............................ 164
Further Readings ........................................ 164

13 Efficacy Assessment ................................ 165
13.1 Introduction ........................................ 165
  13.1.1 Superiority, Equivalence, and Noninferiority Trials ........................................ 165
  13.1.2 Group Sequential and Adaptive Study Designs .......................... 166
13.2 Analysis Populations ................................ 166
  13.2.1 The Intent-to-Treat Population .................... 167
  13.2.2 The Per-protocol Population .................... 167
13.2.3 Using Both Analysis Populations .................................. 167
13.2.4 Missing Data .................................................. 168
13.3 Hypothesis Testing Is Integral to All of the Designs Discussed .................................................. 168
13.4 Superiority Trials .................................................. 169
13.4.1 Well-Defined Study Objectives and Endpoints ................. 169
13.4.2 Analysis of Covariance ........................................ 170
13.4.3 Subgroup Analysis ........................................... 171
13.5 Equivalence Trials .................................................. 172
13.5.1 Why the Hypothesis Testing Strategy Is Different Here .......... 173
13.5.2 Establishing the Equivalence Margin .......................... 174
13.5.3 Hypothesis Construction and Testing ......................... 175
13.5.4 Statistical Analysis and Clinical Judgment Working Together ........................................ 176
13.6 Noninferiority Trials .................................................. 176
13.6.1 Establishing the Noninferiority Margin ......................... 176
13.6.2 Hypothesis Construction and Testing ......................... 176
13.6.3 Statistical Analysis and Clinical Judgment Working Together ........................................ 177
13.7 Group Sequential Designs .......................................... 177
13.7.1 Interim Analyses in Group Sequential Trials .................. 178
13.7.2 Data Monitoring Committees .................................. 178
13.7.3 Statistical Methodology for Interim Analysis ................. 179
13.7.4 Ethical Considerations in Early Termination .................. 182
13.8 Adaptive Designs .................................................. 183
13.8.1 Protocol Amendments ........................................ 183
13.8.2 Increasing Awareness of Adaptive Designs ................... 184
13.8.3 Regulatory Guidance for Adaptive Designs ................... 185
13.9 Bayesian Approaches to Analyzing Clinical Trials ................ 186
13.10 Meta-analysis .................................................... 186
13.10.1 Introduction to Meta-analysis ................................ 187
13.10.2 The Basic Steps ............................................. 188
13.10.3 Choice of the Summary Statistic Representing the Treatment Effect of Interest .................. 189
13.10.4 Data Analysis ............................................... 189
13.10.5 Evaluating Robustness ...................................... 191
13.10.6 Dissemination of Results and Conclusions of a Meta-analysis ........................................ 191
13.11 Therapeutic Use Trials ............................................ 192
13.11.1 Large Simple Therapeutic Trials ............................. 192
14 Cardiac and Cardiovascular Safety Assessments .................. 195
14.1 Introduction ....................................................... 195
14.2 A Three-Component Risk Exclusion Model ....................... 196
14.2.1 Confidence Intervals Facilitate the Determination of Thresholds of Regulatory Concern .................................................. 197
14.3 Cardiac Safety Assessment: A Brief History ......................... 198
14.4 Obtaining QTc Data from QT Measurements ....................... 199
14.5 The Thorough QT/QTc Study ........................................... 200
  14.5.1 Design of the TQT Study ........................................... 200
  14.5.2 TQT Study Conduct ................................................ 201
  14.5.3 Statistical Analysis ............................................... 202
  14.5.4 Ramifications of Interpretations by Sponsors and Regulatory Agencies ......................................................... 203
14.6 FDA Guidance on Excluding Unacceptable Cardiovascular Risk in the Development of Antidiabetic Drugs for Type 2 Diabetes Mellitus .......................... 204
  14.6.1 Clinical Trials to Be Conducted ................................ 204
  14.6.2 Choice of Subject Populations .................................. 205
  14.6.3 Choice of Cardiovascular Endpoints ............................ 205
  14.6.4 Endpoint Adjudication ............................................ 205
  14.6.5 The Required Meta-analysis ...................................... 206
  14.6.6 A Dedicated Large (Simple) Cardiovascular Trial .......... 207
  14.6.7 An Additional Consideration for Safety Meta-analyses .......... 208
14.7 An Example of a Real Safety Meta-analysis .......................... 208
14.8 Potential Regulatory Thresholds of Interest for Other Cardiovascular Parameters ...................................................... 209
Further Readings ..................................................................... 210

15 Manufacturing Small Molecule Drugs and Biologicals ............... 211
15.1 Introduction ..................................................................... 211
15.2 Nonclinical Development ................................................ 212
15.3 Drug Products for Clinical Trials ....................................... 212
  15.3.1 Need for the Investigative Drug and the Control Drug ..... 213
  15.3.2 Blinding of Drug Products for Clinical Trials .......... 213
  15.3.3 Packaging and Distributing Clinical Drug Products .......... 214
15.4 Commercial Manufacturing .............................................. 215
15.5 Quality Control: Building Quality into the Process .................. 215
15.6 Stability Studies ................................................................ 216
15.7 Immediate Release and Modified Release Tablets and Capsules ................................................................. 216
15.8 Recombinant Protein Biologicals ....................................... 217
  15.8.1 Commercial-Scale Manufacturing ............................... 218
Further Readings ..................................................................... 219
Contents

16 Postmarketing Surveillance .................................... 221
16.1 Introduction ........................................... 221
16.2 Limitations of Preapproval Clinical Trials ............... 222
16.3 Individual Differences in Drug Response ................. 223
16.3.1 Hepatic Impairment ................................. 223
16.3.2 Renal Insufficiency ................................ 224
16.3.3 The Elderly ..................................... 224
16.3.4 Pediatric Populations ......................... 225
16.4 Postmarketing Surveillance .............................. 226
16.5 The 2005 CDER Report to the Nation ..................... 227
16.6 The Institute of Medicine’s 2006 Report on Drug Safety .. 228
16.7 The Food and Drug Administration Amendments Act of 2007 ........................................... 229
16.8 The FDA’s 2008 Sentinel Initiative ....................... 230
16.8.1 The Science of Safety ............................. 230
16.8.2 Active Surveillance ............................... 231
Further Readings .............................................. 231

17 Main Themes and Concluding Comments ...................... 233
17.1 Introduction ........................................... 233
17.2 Ethical Considerations .................................. 234
17.3 Design, Methodology, Operations, and Analysis ......... 235
17.3.1 Reducing Bias and Improving Precision ............ 235
17.3.2 Our Definition of Statistics Revisited ............... 236
17.3.3 Numerical Representations of Biological Information .............................................. 236
17.3.4 Some Thoughts on the p-Value ..................... 237
17.4 Confidence Intervals and Clinical Significance .......... 238
17.5 Pharmacokinetics and Pharmacodynamics ................ 238
17.6 Decision-Making ....................................... 239
17.6.1 The Subjective Nature of Many Decisions ......... 239
17.6.2 Determining Thresholds of Regulatory Concern ...... 241
17.7 Benefit–Risk Considerations ............................ 241
17.8 Biological Considerations Pervade Our Discussions .... 241
17.8.1 Biological Underpinnings of Precision Medicine ... 242
17.8.2 Pharmacogenetics ................................ 242
17.8.3 Pharmacogenomics ................................ 243
17.8.4 Pharmacoproteomics ............................... 243
17.9 Integrated Pharmaceutical Medicine .................... 244
17.10 Concluding Comments .................................. 245

References ......................................................... 247

Index .......................................................... 251
New Drug Development
An Introduction to Clinical Trials: Second Edition
Turner, J.R.
2010, XXV, 256 p., Hardcover